Presenting at the annual meeting of the American Society of Clinical Oncology (ASCO), France’s Sanofi (Euronext: SAN) and USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) have released new positive data for their oncology candidate cemiplimab.
The firms are developing the immuno-oncology treatment as part of a long-standing collaboration.
The results, which were published in the New England Journal of Medicine (NEJM), show that certain cutaneous squamous cell carcinoma (CSCC) patients had a 47.5% objective response after nearly eight months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze